{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:55Z","timestamp":1790796235634,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-024-00885-z","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T06:02:16Z","timestamp":1716357736000},"page":"561-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case diagnosed with IgA nephropathy during a complete remission of minimal change nephrotic syndrome treated with rituximab"],"prefix":"10.1007","volume":"13","author":[{"given":"Mana","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"885_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/ncpneuro0901","volume":"4","author":"CD Marinos","year":"2008","unstructured":"Marinos CD. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4:557\u201367.","journal-title":"Nat Clin Pract Neurol"},{"key":"885_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"I Kazumoto","year":"2014","unstructured":"Kazumoto I, Mayumi S, Kandai N, Rintaro M, Nao T, Koichi K, Kenichiro M, Kunihiko A, Koichi N, Yoshiyuki O, Shori T, Ryojiro T, Hiroshi K, Hidefumi N, Kenji I, Shuichi I, Yasuo O. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"885_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"CR Jennifer","year":"2017","unstructured":"Jennifer CR, Mark H, Heather NR. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12:677\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"key":"885_CR4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"S Hitoshi","year":"2011","unstructured":"Hitoshi S, Krzysztof K, Jan N, Zina M, Andrew BH, Matthew BR, Robert JW, Francesco S, Jiri M, Ali GG, Bruce AJ. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"key":"885_CR5","first-page":"554","volume":"30","author":"I de la Torre","year":"2012","unstructured":"de la Torre I, Leandro MJ, Edwards JC, Cambridge G. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol. 2012;30:554\u201360.","journal-title":"Clin Exp Rheumatol"},{"key":"885_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"885_CR7","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1182\/blood-2010-01-266536","volume":"116","author":"EM Henrik","year":"2010","unstructured":"Henrik EM, Daniela F, Claudia G, Christoph L, Karin R, Stefanie S, Eugen F, Capucine D, Hans-Peter T, Andreas R, Thomas D. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116:5181\u201390.","journal-title":"Blood"},{"key":"885_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102466","author":"K Khalaf","year":"2020","unstructured":"Khalaf K, Razzaque AA. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev. 2020. https:\/\/doi.org\/10.1016\/j.autrev.2020.102466.","journal-title":"Autoimmun Rev"},{"key":"885_CR9","first-page":"111","volume":"39","author":"U Chisato","year":"2019","unstructured":"Chisato U, Tomohiko N, Yuji T, Yoshitaka W, Koji S, Hitohiko M, Shuichiro F. A case of a 9-year-old girl who developed IgA nephropathy after rituximab administration for steroid-dependent minimal change nephrotic syndrome. JSPRF. 2019;39:111\u20134 ((in Japanese)).","journal-title":"JSPRF"},{"key":"885_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1159\/000013388","volume":"18","author":"TS Ahuja","year":"1998","unstructured":"Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S. IgA nephropathy in psoriasis. Am J Nephrol. 1998;18:425\u20139.","journal-title":"Am J Nephrol"},{"key":"885_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/jcp.2009.068940","volume":"63","author":"L Diwakar","year":"2010","unstructured":"Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F, Noorani S, Krishna MT, Huissoon A. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol. 2010;63:275\u20137.","journal-title":"J Clin Pathol"},{"key":"885_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6734","author":"Y Nihei","year":"2023","unstructured":"Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura Y, Suzuki Y, Kitamura D. Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv. 2023. https:\/\/doi.org\/10.1126\/sciadv.add6734.","journal-title":"Sci Adv"},{"key":"885_CR13","first-page":"3991","volume":"121","author":"DM Douglas","year":"2011","unstructured":"Douglas DM, Julie K, Cheryl W, Adrian P, Urjana P, Elisa AP, Lesley W, Melissa AEL, Andrew JM, Kathy DM, York P, Lea N, Jeannette YL, Bruce AJ, Jan N, Ann R, Jennifer LG, Jeffrey LB. Mice overexpressing BAFF develop a commensal flora-dependent. IgA-associated nephropathy J Clim Invest. 2011;121:3991\u20134002.","journal-title":"IgA-associated nephropathy J Clim Invest"},{"key":"885_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","volume":"96","author":"JR Myette","year":"2019","unstructured":"Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019;96:104\u201316.","journal-title":"Kidney Int"},{"key":"885_CR15","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1186\/ar2076","volume":"8","author":"V Therese","year":"2006","unstructured":"Therese V, Mikael H, Iva G, Wei Z, Marie W, Christina T, Vivianne M. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:R167.","journal-title":"Arthritis Res Ther"},{"key":"885_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O'Connor","year":"2004","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. BCMA is essential for the survival of long-lived bone marrow plasma cells. J EXP Med. 2004;199:91\u20138.","journal-title":"J EXP Med"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-024-00885-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T02:05:38Z","timestamp":1733018738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-024-00885-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1007\/s13730-024-00885-z","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the patient in the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}